Tevogen (TVGN) Common Equity (2021 - 2026)

Tevogen (TVGN) has reported Common Equity for 6 consecutive years, with $800.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Common Equity rose 8534.6% year-over-year to $800.0 million; the trailing twelve-month figure through Jun 2026 stood at $800.0 million (up 8534.6% YoY), and the FY2025 full-year result was $800.0 million, up 12086.81% from the prior year.
• Common Equity advanced to $800.0 million in Q2 2026 per TVGN's latest filing, from -$9.8 million in the prior quarter.
• Across five years, Common Equity topped out at $800.0 million in Q4 2025 and bottomed at -$94.4 million in Q4 2023.
• Historically, Common Equity has averaged $62.5 million across 5 years, with a median of -$9.7 million in 2025.
• The sharpest annual moves came in 2023 and 2025: Common Equity tumbled 519.45% in 2023, then soared 12086.81% in 2025.
• Over 5 years, Common Equity stood at -$34.0 million in 2022, then plunged by 178.13% to -$94.4 million in 2023, then surged by 92.93% to -$6.7 million in 2024, then jumped by 12086.81% to $800.0 million in 2025, then changed by 0.0% to $800.0 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $800.0 million, -$9.8 million, and $800.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.